The combination of anti‐PD‐L1 immunotherapy plus VEGFR/CDK4/6 targeting agents is well tolerated and active in patients with advanced NSCLC, even in those whose tumors progressed on prior checkpoint blockade. The gene discussed is CDK4; the disease is non-small cell lung carcinoma.